Dutch microsurgical robotics developer Microsure has announced the closing of its Series B funding round. In all, the Eindhoven-based startup raked in 2.7 million euros in new investment thanks to new investor Invest-NL, along with additional support from existing shareholders BOM Brabant Ventures and venture capitalist Innovation Industries, as well as from private investor Ten Cate Investeringsmaatschappij (TCIM). Microsure has earmarked the new funding for continuing the clinical rollout of its CE-approved Musa microsurgical robot assistant.
Musa is the world’s first clinically available CE-certified robot assistant for microsurgeries. The device has been developed by a team of engineers and surgeons, creating a groundbreaking solution and compatible with current operating techniques, instruments and OR equipment. Musa seamlessly scales down motion and filters out tremor to keep a steady hand at any time throughout every microsurgical procedure. This can greatly improve clinical outcomes for various microsurgical indications such as lymphatic-venous anastomosis, distal nerve repair, vascularized tissue transplantation and many other complex microsurgical procedures.
With this investment and the company’s recently appointed CEO Sjaak Deckers, the former boss of two other medtech startups GTX Medical and Sapiens (link in Dutch), the surgical robotics expert is now looking to hit its stride in its next market phase after the Covid-induced delay of Musa. With extra time on its hands due to the pandemic, the company shifted its focus to further develop several improvements for the device, which should be available on the market in 2022.
“Despite the Covid-19 restrictions, our engineers have made tremendous improvements to the current Musa system, and our clinical team gained further adoption experience of microsurgery in the Netherlands with the Musa system,” says Deckers. “Microsure has attracted strong interest from multiple key sites and users from across Europe to further advance its unique robot-assisted microsurgical technology platform. This investment will help us expediting our further clinical validation and adoption across multiple sites. It will scale up our business presence, addressing the unique clinical needs for microsurgeons.”